Advertisement cover the XIX International AIDS Conference (AIDS 2012)

Lipid Profile in Children in PREDICT: Immediate Versus Deferred Nevirapine-Based ART

July/August 2012

PREDICT was a 144-week randomised trial of immediate ART (at CD4 15-24%) versus deferred nevirapine-based ART (at CD4 <15%) conducted in ART-naive Thai and Cambodian children 1-12 years of age with baseline CD4 between 15-24%.1

Suparat Kanjanavanit showed findings from a substudy of PREDICT -- in which the children's fasting lipid profile was compared between arms -- in an oral presentation at IAC 2012.

The study included data from 263 children. Of these, 129 received immediate ART and 194 deferred starting ART. At the time of analysis, 60 children in the deferred arm had started ART and 143 had not started ART.

At baseline, the children's median (IQR) age was 6.5 (4.1-8.5) years, 58% were girls and 57% were Thai. Their median fasting time was 8 hours. There were no significant differences between study arms in clinical characteristics at week 0, see Table 1.

Abnormal lipid levels were defined as: total cholesterol > 200 mg/dL; LDL-cholesterol > 130 mg/dL; HDL-cholesterol ≤ 40 mg/dl and triglyceride > 130 mg/dL.

At week 144, 60 children in the deferred had started ART. At this time point the investigators found dyslipidemia to be significantly less in the immediate arm. They also found the immediate arm had significantly higher total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) but lower triglyceride and TC/HDL ratio than the deferred arm.

In multivariate analysis, the mean differences over 144 weeks between the immediate arm and the deferred arm without ART (n=73) were significant for all lipid parameters, see Table 2.

Table 1: Clinical Characteristics at Week 0 and 144
Parameters Week 0 Week 144 Immediate Deferred
WAZ -1.3 -1.3 -1.3 -1.4
HAZ -1.6 -1.7 -1.5 -1.7
CD4 % 19 20 34 24*
CD4 (cells/mm3) 611 619 977 662*
VL (log10 c/mL) 4.9 4.7 1.7 3.4*
Dislipidemia % 59 67 37 61*

WAZ= weight for age z-score, HAZ = height for age z-score

* p<0.05

Table 2: Treatment Effects on Lipid Profiles
Lipid Profiles Immediate (n=129) vs Deferred Not Started ART (n=143) Immediate (n=129) vs Deferred Started ART (n=60)
Mean Difference (95% CI) p Mean Diff. (95% CI) p
Total cholesterol 20.2 (15.9 to 24.5) <0.001 3.2 (-2.1 to 8.6) 0.24
Triglyceride -9.8 (-16.8 to -2.8) 0.006 -8.1 (-16.2 to 0.04) 0.05
LDL 9.1 (5.5 to 12.9) <0.001 -0.7 (-4.0 to 5.5) 0.76
HDL 13 (10.8 to 15.3) <0.001 4.9 (2.1 to 7.8) 0.001

Dr Kanjanavanit noted that the overall rate of dyslipidemia was reduced from 64% to 37% in immediate treatment arm but increased to 78% in the deferred not starting ART arm.

He also noted that although this comparison was made in a substudy of a randomised trial, the small number of children and short duration of ART in the deferred arm are limitations to the findings.

He concluded, "After 3 years of follow-up, nevirapine-based initiation achieved favourable lipid profile in children with mild to moderate HIV-associated immune deficiency. Less dyslipidemia was found in treatment group compared to deferred group."


  1. HTB. No difference in AIDS-free survival in children starting ART with a CD4% between 15%-24% compared to deferring until less than 15% in the PREDICT trial. 1 August 2011.
  2. Kanjanavanit S et al. Lipid profile in children randomised to immediate versus deferred nevirapine-based antiretroviral therapy in the PREDICT study. 19th International AIDS Conference. 22-27 July 2012, Washington. Oral Abstract MOAB0201.
    View video

Links to other websites are current at date of posting but not maintained.

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.